Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea
Authors' conclusion
In this nationwide population-based study on patients with RA or UC, continued use of JAKi was not associated with a significant risk of subsequent recurrent HZ reactivation.
Study context
- Population
- Patients with rheumatoid arthritis (RA) or ulcerative colitis receiving Janus kinase inhibitor (JAKi) who developed herpes zoster (HZ) reactivation, Korean HIRA data 2007–2021of 3947 on JAKi
- Participants
- 460 patients
- Exposure
- JAKi continuation vs JAKi discontinuation after HZ reactivation
- JAKi continuationn = 386
- JAKi discontinuationn = 74reference
- Outcome
- Subsequent recurrent HZ reactivation
Methodological detailsnationwide population-based, Korean HIRA database
- Nationwide population-based
- Korean HIRA database
Main finding
Recurrent HZ reactivation · median follow-up 1.11 years
Adjusted hazard ratio
0.71
CI 0.29–1.72
P = 0.45
Events by group
As reported in the abstract
Observational data: associations, not effects.
Further findings
HZ reactivation on JAKi (whole cohort) · median 0.95 years (IQR, 0.93-2.58) of therapy
- Patients with HZ reactivation
- 611 (15.5%)
- Incidence rate
- 8.38/100 person-years
- n = 3947 (RA 3540, ulcerative colitis (UC) 407)
Original publication
Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea. Semin Arthritis Rheum. Published 12 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →